B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE‐CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA‐3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL.

Authors :: Rodríguez‐Otero, P.
Ailawadhi, S.
Arnulf, B.
Patel, K.
Cavo, M.
Nooka, A.K.
Manier, S.
Callander, N.
Costa, L.J.
Vij, R.
Bahlis, N.J.
Moreau, P.
Solomon, S.R.
Delforge, M.
Berdeja, J.
Truppel‐Hartmann, A.
Yang, Z.
Favre‐Kontula, L.
Wu, F.
Piasecki, J.
Source :: HemaSphere; May2023 Supplement 1, Vol. 7, p7-8, 2p
Publication Year :: 2023

Full Text Access

Tools